MedTrace Logo

Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RZ-629 in Healthy Subjects and T2D

NCT06829563 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2025-08-21

No results posted yet for this study

Summary

The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) biomarkers in single ascending doses (SAD), food effect, and multiple doses studies of RZ-629 in healthy participants and T2D.

Conditions

Interventions

DRUG

RZ-629

Administered orally

DRUG

Placebo

Administered orally

OTHER

Fasted

Participants will be treated with RZ-629 in fasted or fed condition and then cross over after washout

OTHER

Fed

Participants will be treated with RZ-629 in fasted or fed condition and then cross over after washout

Sponsors & Collaborators

  • Rezubio Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-30
Primary Completion
2025-12-20
Completion
2026-02-20
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06829563 on ClinicalTrials.gov